MX336675B - Cribado para compuestos anticancerigenos utilizando actividad de netrina-1. - Google Patents
Cribado para compuestos anticancerigenos utilizando actividad de netrina-1.Info
- Publication number
- MX336675B MX336675B MX2008011067A MX2008011067A MX336675B MX 336675 B MX336675 B MX 336675B MX 2008011067 A MX2008011067 A MX 2008011067A MX 2008011067 A MX2008011067 A MX 2008011067A MX 336675 B MX336675 B MX 336675B
- Authority
- MX
- Mexico
- Prior art keywords
- netrin
- cancer
- screening
- activity
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000009065 Netrin-1 Human genes 0.000 title abstract 3
- 108010074223 Netrin-1 Proteins 0.000 title abstract 3
- 230000001093 anti-cancer Effects 0.000 title abstract 2
- 238000012216 screening Methods 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000005951 Netrin Receptors Human genes 0.000 abstract 2
- 108010030865 Netrin Receptors Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 206010055113 Breast cancer metastatic Diseases 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 238000006471 dimerization reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un método in vitro para el cribado de compuestos anticancerígenos en base en la capacidad de estos compuestos de interactuar con el receptor de netrina-1 y/o para inhibir la dimerización del dominio intracelular del receptor de netrina-1 expresado en células tumorales; la invención también se relaciona con un método para predecir la presencia de cáncer metastásico o agresivo o para determinar la eficiencia de un tratamiento anticanceroso en base en la medición del nivel de expresión de netrina-1; la invención comprende adicionalmente equipos y compuestos como un medicamento para el tratamiento de cáncer tal como cáncer de mama metastásico, relacionado con la sobreexpresión de netrina-1 por las células tumorales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77692606P | 2006-02-28 | 2006-02-28 | |
| PCT/EP2007/051920 WO2007099133A1 (en) | 2006-02-28 | 2007-02-28 | Screening for anti-cancer compounds using netrin-1 activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2008011067A MX2008011067A (es) | 2008-11-25 |
| MX336675B true MX336675B (es) | 2016-01-27 |
Family
ID=38051332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008011067A MX336675B (es) | 2006-02-28 | 2007-02-28 | Cribado para compuestos anticancerigenos utilizando actividad de netrina-1. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20090226458A1 (es) |
| EP (1) | EP1989546B1 (es) |
| JP (1) | JP5602368B2 (es) |
| KR (2) | KR101587932B1 (es) |
| CN (1) | CN101389958B (es) |
| AU (1) | AU2007220515B2 (es) |
| BR (1) | BRPI0707040B8 (es) |
| CA (1) | CA2638974C (es) |
| CY (1) | CY1118325T1 (es) |
| DK (1) | DK1989546T3 (es) |
| ES (1) | ES2601352T3 (es) |
| HU (1) | HUE030738T2 (es) |
| IL (1) | IL193580A (es) |
| LT (1) | LT1989546T (es) |
| MX (1) | MX336675B (es) |
| PL (1) | PL1989546T3 (es) |
| PT (1) | PT1989546T (es) |
| SG (1) | SG172645A1 (es) |
| SI (1) | SI1989546T1 (es) |
| WO (1) | WO2007099133A1 (es) |
| ZA (1) | ZA200806913B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229485A1 (en) * | 2008-05-21 | 2011-09-22 | Centre National De La Recherche Scientfique (Cnrs) | Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma |
| WO2009141440A1 (en) * | 2008-05-21 | 2009-11-26 | Centre National De La Recherche Scientifique (Cnrs) | Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma |
| EP2208738A1 (en) | 2009-01-09 | 2010-07-21 | Centre National pour la Recherche Scientifique (CNRS) | Method for the selection of endothelial cells death inducers via netrin-1 and its applications |
| US8052960B2 (en) * | 2009-01-20 | 2011-11-08 | The Penn State Research Foundation | Netrin-1 as a biomarker of injury and disease |
| EP2267153A1 (en) * | 2009-05-26 | 2010-12-29 | Université Claude Bernard Lyon 1 | Identification of netrin-1 receptor unc5c gene mutation in solid cancers |
| WO2011150299A2 (en) * | 2010-05-28 | 2011-12-01 | The Regents Of The University Of California | Treatment of myocardial infarction and vascular injury with netrin-1 |
| KR20140004632A (ko) * | 2010-08-26 | 2014-01-13 | 에프. 호프만-라 로슈 아게 | DCC의 제 5 피브로넥틴 유형 III 도메인의 재조합 Fc-융합 단백질 |
| EP2773962B1 (en) * | 2011-11-04 | 2016-09-14 | Invivis SAS | Assay for predictive biomarkers of anti-estrogen efficacy |
| EP2708241A1 (en) | 2012-09-12 | 2014-03-19 | Netris Pharma | Recombinant Fc-fusion protein of the two Immunoglobulin domains of UNC5 |
| EP2708231A1 (en) | 2012-09-12 | 2014-03-19 | Netris Pharma | Combined treatment with netrin-1 interfering drug and chemotherapeutic drug |
| EP2893939A1 (en) | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
| CN105031611B (zh) * | 2015-06-18 | 2018-02-09 | 中国医学科学院基础医学研究所 | netrin‑1蛋白在制备用于肿瘤治疗的药物中的用途 |
| AR106543A1 (es) | 2015-11-02 | 2018-01-24 | Netris Pharma | Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético |
| CN107011444B (zh) * | 2016-01-28 | 2021-11-16 | 中国科学院脑科学与智能技术卓越创新中心 | 一种筛选hERG钾离子通道激动剂和毒性检测方法 |
| US10379534B2 (en) * | 2016-01-28 | 2019-08-13 | Qualcomm Incorporated | Drone flight control |
| CN105925578A (zh) * | 2016-05-30 | 2016-09-07 | 东北师范大学 | 靶向沉默Neogenin的shRNA |
| JP7211952B2 (ja) | 2017-01-05 | 2023-01-24 | ネトリス ファーマ | ネトリン－１干渉薬及び免疫チェックポイント阻害薬による併用治療 |
| US20230204565A1 (en) * | 2020-01-02 | 2023-06-29 | The Regents Of The University Of California | Methods for Culturing Cancer Cells and for Inhibiting Invasion of Cancer |
| CN112812167B (zh) * | 2021-01-06 | 2023-04-11 | 东北师范大学 | 一种促进细胞存活的Netrin-1模拟肽、Netrin-1截短多肽及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3611194A1 (de) * | 1986-04-04 | 1987-10-08 | Bayer Ag | Cancerostatisches mittel |
| US5565331A (en) | 1993-11-12 | 1996-10-15 | The Regents Of The University Of California | Nucleic acids encoding neural axon outgrowth modulators |
| US6030806A (en) | 1995-06-30 | 2000-02-29 | Landes; Gregory M. | Human chromosome 16 genes, compositions, methods of making and using same |
| JPH11509408A (ja) | 1995-06-30 | 1999-08-24 | ジェンザイム コーポレイション | 新規なヒト第１６染色体遺伝子、組成物、それらの製造および使用方法 |
| US5824775A (en) * | 1996-04-19 | 1998-10-20 | The Regents Of The University Of California | Human netrin-1 |
| JPH11335398A (ja) | 1998-05-22 | 1999-12-07 | Hoechst Marion Roussel Kk | 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬 |
| US5939271A (en) * | 1997-02-19 | 1999-08-17 | The Regents Of The University Of California | Netrin receptor |
| US20060025335A1 (en) * | 2004-01-30 | 2006-02-02 | Kinane Thomas B | Netrin compositions and methods of using the same |
| JP2008509655A (ja) * | 2004-06-04 | 2008-04-03 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | Ｕｎｃ５ｈ２のスプライス変異体 |
| AU2005275062A1 (en) * | 2004-07-14 | 2006-02-23 | University Of Utah Research Foundation | Netrin-related compositions and uses |
| CA2587921A1 (fr) | 2004-11-22 | 2006-05-26 | Centre National De La Recherche Scientifique | Netrine 4 mutee, ses fragments et leur utilisation comme medicaments |
| US20060153840A1 (en) * | 2005-01-12 | 2006-07-13 | Anne Eichmann | Methods for preventing or treating a condition or a disease associated with angiogenesis |
| CA2489780A1 (en) | 2005-01-12 | 2006-07-12 | Inserm | Methods for preventing or treating a condition or a disease associated with angiogenesis |
| JP4677376B2 (ja) | 2006-07-07 | 2011-04-27 | キヤノン株式会社 | 画像処理装置、画像処理方法、画像処理プログラム及び記憶媒体 |
| WO2009141440A1 (en) * | 2008-05-21 | 2009-11-26 | Centre National De La Recherche Scientifique (Cnrs) | Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma |
-
2007
- 2007-02-28 ES ES07726556.9T patent/ES2601352T3/es active Active
- 2007-02-28 JP JP2008556779A patent/JP5602368B2/ja active Active
- 2007-02-28 PT PT77265569T patent/PT1989546T/pt unknown
- 2007-02-28 HU HUE07726556A patent/HUE030738T2/en unknown
- 2007-02-28 KR KR1020147029279A patent/KR101587932B1/ko active Active
- 2007-02-28 LT LTEP07726556.9T patent/LT1989546T/lt unknown
- 2007-02-28 SG SG2011038783A patent/SG172645A1/en unknown
- 2007-02-28 BR BRPI0707040A patent/BRPI0707040B8/pt active IP Right Grant
- 2007-02-28 AU AU2007220515A patent/AU2007220515B2/en active Active
- 2007-02-28 DK DK07726556.9T patent/DK1989546T3/en active
- 2007-02-28 CN CN200780006936.3A patent/CN101389958B/zh active Active
- 2007-02-28 WO PCT/EP2007/051920 patent/WO2007099133A1/en not_active Ceased
- 2007-02-28 SI SI200731865A patent/SI1989546T1/sl unknown
- 2007-02-28 CA CA2638974A patent/CA2638974C/en active Active
- 2007-02-28 EP EP07726556.9A patent/EP1989546B1/en active Active
- 2007-02-28 KR KR1020087022051A patent/KR20080113368A/ko not_active Ceased
- 2007-02-28 US US12/224,384 patent/US20090226458A1/en not_active Abandoned
- 2007-02-28 PL PL07726556T patent/PL1989546T3/pl unknown
- 2007-02-28 MX MX2008011067A patent/MX336675B/es unknown
-
2008
- 2008-08-12 ZA ZA200806913A patent/ZA200806913B/xx unknown
- 2008-08-20 IL IL193580A patent/IL193580A/en active IP Right Grant
-
2014
- 2014-09-15 US US14/486,124 patent/US20150004159A1/en not_active Abandoned
-
2016
- 2016-10-26 CY CY20161101087T patent/CY1118325T1/el unknown
-
2018
- 2018-06-21 US US16/014,529 patent/US11203641B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX336675B (es) | Cribado para compuestos anticancerigenos utilizando actividad de netrina-1. | |
| WO2011088149A3 (en) | Methods for predicting response of triple-negative breast cancer to therapy | |
| EP2331136A4 (en) | FRIZZLED-BINDING SUBSTANCES AND ITS USES | |
| MX346973B (es) | Anticuerpos especificos de tumores y usos para los mismos. | |
| WO2005113816A3 (en) | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer | |
| MX2009008470A (es) | Particulas para detectar objetivos intracelulares. | |
| TR201903981T4 (tr) | Kanser tedavisi için bileşikler. | |
| AU2010220421A8 (en) | Antibodies against a proliferating inducing ligand (APRIL) | |
| WO2008104543A3 (en) | Method for predicting the occurrence of metastasis in breast cancer patients | |
| GB201021289D0 (en) | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer | |
| IL182423A0 (en) | Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer | |
| MY155621A (en) | Axl antibodies | |
| WO2012058592A3 (en) | Non-antagonistic egfr-binding molecules and immunoconjugates thereof | |
| EP3683320A3 (en) | Mirna fingerprint in the diagnosis of lung cancer | |
| EA200970108A1 (ru) | Композиции и способы для ингибирования роста smad4-дефицитных форм рака | |
| MX2010008496A (es) | Metodo para la determinacion de sensibilidad a agente anticancerigeno. | |
| WO2010004591A3 (en) | Genetic variants for breast cancer risk assessment | |
| WO2012109632A3 (en) | Crown-like structures as a biomarker for cancer risk and cancer prognosis | |
| WO2012093821A3 (ko) | 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법 | |
| WO2013025952A3 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| WO2008115750A3 (en) | Compositions and methods for the treatment of cancer | |
| WO2009019370A3 (fr) | Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal | |
| WO2010120143A3 (ko) | 간암 예후 마커 | |
| WO2009055823A3 (en) | Method to predict responsiveness of breast cancer to polyaminetype chemotherapy | |
| WO2007120787A3 (en) | Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression |